These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11890365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA.
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. GTI-2040. Lorus Therapeutics.
    Orr RM.
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM.
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [Abstract] [Full Text] [Related]

  • 12. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
    Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA.
    Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS.
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [Abstract] [Full Text] [Related]

  • 16. Genasense (Genta Inc).
    Banerjee D.
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
    Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P, European Organization for Research and Treatment of Cancer (EORTC).
    Eur J Cancer; 2001 Nov; 37(17):2194-8. PubMed ID: 11677106
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
    Schmitz G.
    Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.